Skip to main content
Cloudbreak Pharma Inc. logo

Cloudbreak Pharma Inc. — Investor Relations & Filings

Ticker · 2592 HKEX Manufacturing
Open in API
Filings indexed 71 across all filing types
Latest filing 2025-09-30 Board/Management Inform…
Country HK Hong Kong
Listing HKEX 2592

About Cloudbreak Pharma Inc.

https://cloudbreakpharma.com/

Cloudbreak Pharma Inc. is an innovative, clinical-stage ophthalmology biotechnology company dedicated to the research and development of novel and differentiated treatments for chronic eye diseases. The company focuses on improving vision quality globally by developing therapies for both anterior and posterior segment ophthalmic conditions. Its robust pipeline includes products targeting pterygium, pinguecula, meibomian gland dysfunction, glaucoma filtration surgery, age-related macular degeneration, and diabetic retinopathy. Cloudbreak utilizes advanced platforms, including a potent multi-kinase inhibitor formulated as a topical eye drop for anterior segment diseases and a unique Antibody-Drug Synergism Platform for posterior segment diseases.

Recent filings

Filing Released Lang Actions
(1) RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR&#x3b; (2) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR&#x3b; AND (3) CHANGE OF COMPOSITION OF BOARD COMMITTEES
Board/Management Information Classification · 1% confidence The document is an official announcement by Cloudbreak Pharma Inc. regarding the resignation of an independent non-executive director, the appointment of a new independent non-executive director, and related changes to board committees. It does not include financial results, regulatory form disclosures, or meeting materials; rather, it concerns changes in board composition, which falls squarely under 'Board/Management Information'.
2025-09-30 English
Arrangement of Electronic Dissemination of Corporate Communications to non-registered shareholders
Regulatory Filings Classification · 1% confidence The document is a shareholder communication notice regarding electronic dissemination of corporate communications and includes a request form for printed copies. It is not a financial report, earnings release, proxy solicitation, or management change notice; it is an operational/regulatory announcement about distribution methods of company documents. This falls under the general “Regulatory Filings” fallback category.
2025-09-25 English
Arrangement of Electronic Dissemination of Corporate Communications to shareholder
Regulatory Filings Classification · 1% confidence The document is a letter to shareholders regarding the arrangements for electronic dissemination of all future corporate communications under Hong Kong Listing Rule 2.07A. It is not an AGM material, financial report, earnings release, management or proxy statement, nor a specific report publication. It is a general regulatory announcement about communication policy. There is no specific category for an electronic dissemination notice, so it falls under the fallback category for miscellaneous regulatory filings.
2025-09-25 English
INTERIM REPORT 2025
Interim / Quarterly Report Classification · 1% confidence The document is explicitly titled '2025 INTERIM REPORT' and '2025 中期報告'. It contains comprehensive financial statements including the Condensed Consolidated Interim Statement of Comprehensive Income, Statement of Financial Position, Statement of Changes in Equity, and Statement of Cash Flows, along with detailed notes and management discussion. It is a full interim financial report for the six-month period ended June 30, 2025, not an announcement or a summary. H1 2025
2025-09-25 English
GRANT OF RSUs UNDER THE POST-IPO EQUITY INCENTIVE SCHEME
Share Issue/Capital Change Classification · 1% confidence The document is a Hong Kong Stock Exchange announcement under Listing Rules 17.06A/B/C regarding the grant of restricted share units (RSUs) under the company’s post-IPO equity incentive scheme. It details the number of RSUs awarded, vesting schedules, and related terms—i.e., an issuance of share‐linked awards that will give rise to eventual share issuance under the incentive plan. This is not a full annual or interim report, nor an earnings release, nor a director share transaction, but rather a notice of share issuance/ capital change under the incentive scheme. Therefore, it best fits into the “Share Issue/Capital Change” category (SHA).
2025-09-18 English
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2025
Regulatory Filings Classification · 1% confidence The document is a standardized monthly return (Form FF301) filed with the Hong Kong Stock Exchange under Chapter 19B listing rules, detailing movements in authorized share capital, issued shares, and share options. It is neither an earnings release, AGM materials, management change, nor a standalone financial report; rather, it is a routine regulatory compliance filing. It does not announce a single capital change event but provides a monthly summary as required by listing rules. Therefore, the correct classification is a general Regulatory Filing.
2025-09-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.